Indiana could expand health insurance coverage for low-income Hoosiers entirely through private health insurance plans under an amendment adopted by a House committee on Monday. The change was immediately criticized by the Pence administration.
Indiana’s laws requiring hospitals to release price information are woefully inadequate, according to a report by two health insurance reform groups. Indiana was among 29 states to receive an "F" grade.
An Indiana House panel has altered a plan that would use the state's Healthy Indiana Plan to expand Medicaid coverage in the state.
Johnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.
The Carmel-based insurance holding company says it expects to buy back more of its shares and take a special charge tied to a recent tender offer.
The biggest changes from President Obama’s 2010 health reform law take effect nine months from now, so many Hoosier employers have started crunching detailed numbers to cost out their options.
A study by the nation's leading group of financial risk analysts shows the biggest driver of health insurance premiums will rise by more than 67 percent for Indiana residents' individual policies under President Barack Obama's health care overhaul.
Eli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker Boehringer Ingelheim to the Food and Drug Administration.
Consumers would face tighter limits on the quantities they could buy of cold and allergy pills often used to make methamphetamine under a proposal approved by Indiana lawmakers.
A central Indiana REIT that went public in 2012 has agreed to buy 13 senior housing and care facilities in three states, growing its asset value by 50 percent.
The Indiana Health Information Exchange Inc. hopes to raise roughly $20 million over three years to take its health information technology services to hospitals around the country.
Gov. Mike Pence’s strategy for expanding Medicaid in Indiana is to convince or cajole the Obama administration to let him use the Healthy Indiana Plan to do it. A recent deal in Arkansas seems to make it more likely that the Obama team will give Pence what he wants.
Eli Lilly and Co. granted larger bonuses to its top five executives early this year, which boosted their 2012 compensation anywhere from 3 percent to 8 percent.
Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines.
Hospital officials praised Indiana's medical savings accounts but some consumer advocates panned them Wednesday during a public hearing as Gov. Mike Pence seeks federal approval to use the Healthy Indiana Plan to expand Medicaid in this state.
A big bet on employer-sponsored retirement plans is paying off for locally based OneAmerica Financial Partners, a company best known for its life insurance offerings.
The debate over expanding Medicaid in Indiana so far has hinged on how much it will cost. But two recent studies suggest Hoosier employers should be focused on how much a Medicaid expansion will save them: perhaps as much as $400 million per year.
The insurer will invest millions to lease, renovate and equip a 109,000-square-foot customer service center at 101 W. 103rd St. It plans to begin hiring immediately, and bring up to 1,200 new jobs by 2016.
House Bill 1315, which is scheduled for a Senate floor hearing on Monday, would require pharmacists to check with a patient’s physician before automatically substituting a generic version of a biotech drug for a brand-name version.
Shares of several pharmaceutical companies that make diabetes medicines, including Eli Lilly, fell after U.S. regulators warned they are looking into potential risks of drugs in two classes of diabetes treatments.
